Clinical trials: Macular Disease
Macular Degeneration
Vision Improvement for Patients With Age-Related Macular Degeneration
This study is being conducted to assess the safety and efficacy of the VIS, LLC (VIS) Opti-K Low Vision Aid Device and treatment to provide vision improvement to patients with age-related macular degeneration.
- Trial name
- NCT06198452
- Testing
- Vision Improvement
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- VIS, Inc.
Visual Acuity, Geographic Atrophy
A Study to Evaluate the Safety and Clinical Response of Subretinal Administration of CNTO 2476 in Participants With Geographic Atrophy
The purpose of this study is to evaluate the safety and performance profile of the suprachoroidal surgical approach and the Delivery System.
- Conditions
- Visual Acuity, Geographic Atrophy, Macular Degeneration
- Trial name
- PRELUDE (NCT02659098)
- Testing
- CNTO 2476 3.0 x 10^5 cells, Subretinal Delivery System
- Where
- 8 sites in United States
- Volunteers
- 21 people
- Sponsor
- Janssen Research & Development, LLC
Age-Related Macular Degeneration, Geographic Atrophy
Multicenter Clinical Study of the SING-IMT in Patients with Late-stage AMD
The objective of this study is to determine the safety and effectiveness of the smaller incision, new generation (SING), implantable miniature telescope (IMT) in patients with moderate-severe central vision loss due to late-stage…
- Trial name
- CONCERTO (NCT05438732)
- Testing
- smaller incision, new generation implantable miniature telescope (SING-IMT)
- Where
- 10 sites in United States
- Volunteers
- 125 people
- Sponsor
- VisionCare, Inc.
Macular Degeneration
A Study to Evaluate Abicipar Pegol for Safety and Treatment Effect in Participants With Neovascular Age-related Macular Degeneration (AMD)
The objective of this study is to evaluate abicipar pegol for safety and treatment effects in participants with neovascular age-related macular degeneration (AMD).
- Trial name
- NCT03539549
- Testing
- Abicipar pegol
- Where
- 37 sites in United States
- Volunteers
- 124 people
- Sponsor
- Allergan
Neovascular Age-related Macular Degeneration
A Randomized, Double-masked, Multicenter,Sham-controlled, Safety and Efficacy Study of KH902 in Patients With Wet AMD
This study is designed to prove and confirm the efficacy and safety of multiple injections of human recombinant vascular endothelial growth factor receptor-Fc fusion protein (KH902) in patients with choroidal neovascularization…
- Trial name
- PHOENIX (NCT01436864)
- Testing
- Recombinant Human VEGF Receptor-Fc Fusion Protein
- Where
- 11 sites in China
- Volunteers
- 125 people
- Sponsor
- Chengdu Kanghong Biotech Co., Ltd.
Neovascular (Wet) Age-Related Macular Degeneration
Safety and Efficacy of AIV007 Periocular Injection in Patients With Neovascular Age-Related Macular Degeneration
The goal of this study is to evaluate whether AIV007 provides benefits to patients with neovascular age-related macular degeneration in improving vision and that it has an acceptable safety profile.
- Trial name
- NCT07557121
- Testing
- AIV007, EYLEA® (aflibercept) Injection 2 mg (0.05mL)
- Where
- 2 sites in United States
- Volunteers
- 35 people
- Sponsor
- AiViva BioPharma, Inc.
Neovascular Age-Related Macular Degeneration
A Non-interventional Study to Assess the Influence of Automated Optical Coherence Tomography Image Enrichment With Segmentation Information on Disease Activity Assessment in Patients Treated With Licensed Anti- VEGF Injections
RAZORBILL was an observational, multicenter, multinational, open-label, study designed primarily to investigate the influence of automated OCT image enrichment with segmentation information on disease activity assessment in nAMD…
- Trial name
- RAZORBILL (NCT04662944)
- Testing
- brolucizumab, ranibizumab, aflibercept
- Where
- 17 sites in Canada, Germany and 3 more
- Volunteers
- 494 people
- Sponsor
- Novartis Pharmaceuticals
Wet Macular Degeneration
A Study to Test Different Doses of BI 836880 in Patients With an Eye Disease Called Wet Age-related Macular Degeneration (wAMD)
This is a study in people with an eye disease called wet age-related macular degeneration (wAMD). The purpose of the study is to find out how well different doses of a medicine called BI 836880 are tolerated.
- Trial name
- NCT03861234
- Testing
- BI 836880
- Where
- 14 sites in United States, Germany and 1 more
- Volunteers
- 43 people
- Sponsor
- Boehringer Ingelheim
Age-Related Maculopathy
Safety and Effectiveness Investigation for Dry, Non-Exudative Age Related Macular Degeneration (AMD) Using Rheopheresis
SUMMARY Age-related macular degeneration (AMD) is the leading cause of late onset visual impairment and legal blindness in people 65 years of age or older in the United States.
- Trial name
- RHEO-AMD (NCT00460967)
- Testing
- Rheopheresis
- Where
- 39 sites in United States, Canada and 1 more
- Volunteers
- 325 people
- Sponsor
- OccuLogix
Macular Edema, Retinal Vein Occlusion
Suprachoroidal Injection of Triamcinolone Acetonide With IVT Anti-VEGF in Subjects With Macular Edema Following RVO
This Phase 3, multicenter, randomized, masked, controlled, parallel group study is designed to demonstrate that suprachoroidal (SC) CLS-TA administered with intravitreal (IVT) anti-VEGF agent in subjects with treatment naive RVO…
- Trial name
- TOPAZ (NCT03203447)
- Testing
- suprachoroidal CLS-TA, Lucentis or Avastin
- Where
- 92 sites in United States, Australia and 3 more
- Volunteers
- 325 people
- Sponsor
- Clearside Biomedical, Inc.
Geographic Atrophy, Macular Degeneration
A Safety and Efficacy Study of Brimonidine Intravitreal Implant in Geographic Atrophy Secondary to Age-related Macular Degeneration
This study will assess the safety and efficacy of the brimonidine intravitreal implant in participants with geographic atrophy due to age-related macular degeneration.
- Trial name
- BEACON (NCT02087085)
- Testing
- 400 µg Brimonidine Implant
- Where
- 41 sites in United States, Australia and 4 more
- Volunteers
- 310 people
- Sponsor
- Allergan
Stargardt Disease, Stargardt Macular Degeneration
Phase 2 Tolerability and Effects of ALK-001 on Stargardt Disease
The purpose of this study is to determine the long term safety and tolerability of ALK-001 (C20-D3-retinyl acetate), and to explore the effects of ALK-001 on the progression of Stargardt disease in patients between the ages of 8…
- Conditions
- Stargardt Disease, Stargardt Macular Degeneration, Stargardt Macular Dystrophy, Autosomal Recessive Stargardt Disease 1 (ABCA4-related)
- Trial name
- TEASE (NCT02402660)
- Testing
- ALK-001
- Where
- 14 sites in United States
- Volunteers
- 160 people
- Sponsor
- Alkeus Pharmaceuticals, Inc.
Retinal Vein Occlusion, Macular Edema
A Retrospective Study of Anti-Vascular Endothelial Growth Factor (VEGF) Injections for Retinal Vein Occlusion or Diabetic Macular Edema
This retrospective data review study will evaluate anti-VEGF injections for retinal vein occlusion (RVO) or diabetic macular edema (DME).
- Trial name
- NCT01918371
- Testing
- Anti-VEGF
- Where
- United States
- Volunteers
- 323 people, healthy volunteers welcome
- Sponsor
- Allergan
Age Related Macular Degeneration
Usage of the Home Macular Perimeter (HMP)
Demonstrate the ability of the current interactive tutorial and 1-800 support to teach an AMD patient to use the HMP device.
- Trial name
- HMP (NCT00596388)
- Where
- Israel
- Volunteers
- 20 people
- Sponsor
- Notal Vision Ltd.
Normal Eyes, Age Related Macular Degeneration
High Resolution Imaging OCT Study
The goal of this pilot study is to compare image quality between the investigational devices (R1 and HighRes OCT) and the SPECTRALIS (cleared) in adult participants with normal and/or pathology eyes.
- Conditions
- Normal Eyes, Age Related Macular Degeneration, Diabetic Retinopathy, Eyes With Retinal Diseases
- Trial name
- NCT07338461
- Testing
- Autofluorescence Imaging, Infrared reflectance imaging, OCT imaging
- Where
- Italy
- Volunteers
- 97 people, healthy volunteers welcome
- Sponsor
- Heidelberg Engineering GmbH
Geographic Atrophy
CLG561 Proof-of-Concept Study as a Monotherapy and in Combination With LFG316 in Subjects With Geographic Atrophy (GA)
The purpose of this study is to evaluate the safety and efficacy of 12 (every 28 days) intravitreal (IVT) injections of CLG561 as a monotherapy and in combination with LFG316 as compared to sham in subjects with geographic…
- Trial name
- NCT02515942
- Testing
- CLG561, LFG316
- Volunteers
- 114 people
- Sponsor
- Alcon Research
Macular Degeneration, Age-Related Macular Degeneration
A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)
Researchers are looking for new ways to treat neovascular age-related macular degeneration (NVAMD). Available standard (usual) treatments for NVAMD, such as aflibercept, may not work for every person.
- Conditions
- Macular Degeneration, Age-Related Macular Degeneration, Choroidal Neovascularization, Wet Macular Degeneration
- Trial name
- MALBEC (NCT07440225)
- Testing
- Tiespectus, Aflibercept
- Where
- 132 sites in United States, Argentina and 10 more
- Volunteers
- 960 people
- Sponsor
- EyeBiotech Ltd.
Macular Degeneration
Double-Masked Study of Photrex (Rostaporfin) Photodynamic Therapy in the Treatment of Age-Related Macular Degeneration
The purpose of this study is to confirm the efficacy and safety of rostaporfin (PHOTREX) photodynamic therapy (PDT) in the treatment of classic and occult subfoveal choroidal neovascularization (CNV) associated with age-related…
- Trial name
- NCT00157976
- Testing
- Photrex (rostaporfin)
- Where
- 4 sites in Bulgaria, Czechia and 2 more
- Volunteers
- 660 people
- Sponsor
- Miravant Pharmaceuticals
Wet Age-related Macular Degeneration
Phase 3 Study of Intravitreal OLN324 in Adults With Neovascular (Wet) Age-related Macular Degeneration (nAMD) (OLN324-CP-05)
This is a Phase 3 study of an investigational drug called OLN324, which is being developed by Ollin Biosciences as a treatment for patients with neovascular (wet) age-related macular degeneration (nAMD).
- Trial name
- SAHARA (NCT07816289)
- Testing
- OLN324, Ranibizumab
- Volunteers
- 400 people
- Sponsor
- Ollin Biosciences, Inc.
Macular Degeneration
Study to Assess the EffectiVeness of exIsting Anti-vascular Endothelial groWth Factor (Anti-VEGF) Treatment Regimens in Patients With Wet Age-related Macular Degeneration
Retrospective, non-interventional, observational multi-center field study. Patients diagnosed with wet Age-related macular degeneration (wAMD) and having started treatment with ranibizumab between January 1, 2009 and December 31…
- Trial name
- REVIEW (NCT01933152)
- Testing
- Ranibizumab
- Where
- Portugal
- Volunteers
- 137 people
- Sponsor
- Bayer